Zithromax Cardiovascular Safety Label Revision May Resemble Levaquin
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is reviewing a large study published in the New England Journal of Medicine, and strengthened warnings about cardiovascular risk may be on the way for all azithromycin products.